These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
47. Hepatitis B Virus Core Particles Containing a Conserved Region of the G Protein Combined with Interleukin-35 Protected Mice against Respiratory Syncytial Virus Infection without Vaccine-Enhanced Immunopathology. Yang J; Ma C; Zhao Y; Fan A; Zou X; Pan Z J Virol; 2020 Jun; 94(13):. PubMed ID: 32321805 [TBL] [Abstract][Full Text] [Related]
49. Modelling the impact of respiratory syncytial virus (RSV) vaccine and immunoprophylaxis strategies in New Zealand. Prasad N; Read JM; Jewell C; Waite B; Trenholme AA; Huang QS; Grant CC; Newbern EC; Hogan AB Vaccine; 2021 Jul; 39(31):4383-4390. PubMed ID: 34147296 [TBL] [Abstract][Full Text] [Related]
50. A number-needed-to-treat analysis of the use of respiratory syncytial virus immune globulin to prevent hospitalization. Robbins JM; Tilford JM; Jacobs RF; Wheeler JG; Gillaspy SR; Schutze GE Arch Pediatr Adolesc Med; 1998 Apr; 152(4):358-66. PubMed ID: 9559712 [TBL] [Abstract][Full Text] [Related]
51. Cost of hospitalization for respiratory syncytial virus chest infection and implications for passive immunization strategies in a developing nation. Chan PW; Abdel-Latif ME Acta Paediatr; 2003 Apr; 92(4):481-5. PubMed ID: 12801117 [TBL] [Abstract][Full Text] [Related]
52. Respiratory syncytial virus vaccine research and development: World Health Organization technological roadmap and preferred product characteristics. Vekemans J; Moorthy V; Giersing B; Friede M; Hombach J; Arora N; Modjarrad K; Smith PG; Karron R; Graham B; Kaslow DC Vaccine; 2019 Nov; 37(50):7394-7395. PubMed ID: 29395536 [TBL] [Abstract][Full Text] [Related]
53. Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment. Power UF; Plotnicky-Gilquin H; Huss T; Robert A; Trudel M; Ståhl S; Uhlén M; Nguyen TN; Binz H Virology; 1997 Apr; 230(2):155-66. PubMed ID: 9143271 [TBL] [Abstract][Full Text] [Related]
54. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173 [TBL] [Abstract][Full Text] [Related]
55. A Parainfluenza Virus Vector Expressing the Respiratory Syncytial Virus (RSV) Prefusion F Protein Is More Effective than RSV for Boosting a Primary Immunization with RSV. Liang B; Matsuoka Y; Le Nouën C; Liu X; Herbert R; Swerczek J; Santos C; Paneru M; Collins PL; Buchholz UJ; Munir S J Virol; 2020 Dec; 95(2):. PubMed ID: 33115876 [TBL] [Abstract][Full Text] [Related]
56. Sendai virus-based RSV vaccine protects against RSV challenge in an in vivo maternal antibody model. Jones BG; Sealy RE; Surman SL; Portner A; Russell CJ; Slobod KS; Dormitzer PR; DeVincenzo J; Hurwitz JL Vaccine; 2014 May; 32(26):3264-73. PubMed ID: 24721531 [TBL] [Abstract][Full Text] [Related]
57. Physiologic risk factors for respiratory viral infections and immunoprophylaxis for respiratory syncytial virus in young children with congenital heart disease. Cabalka AK Pediatr Infect Dis J; 2004 Jan; 23(1 Suppl):S41-5. PubMed ID: 14730269 [TBL] [Abstract][Full Text] [Related]
58. Involvement of the complement system in the protection of mice from challenge with respiratory syncytial virus Long strain following passive immunization with monoclonal antibody 18A2B2. Corbeil S; Seguin C; Trudel M Vaccine; 1996 Apr; 14(6):521-5. PubMed ID: 8782350 [TBL] [Abstract][Full Text] [Related]
59. [Strategies and recommendations to face respiratory syncytial virus disease in 2024]. Paris E; Daza P; Tapia L; Díaz JP; Cruces Romero P; Castillo A; González C; Endeiza ML; Jofré L; Castro F; Zamorano A; Rodríguez J; Acevedo J; Santa Cruz T; González J; Escárate R; Moreno JP; Cisternas P Andes Pediatr; 2024 Feb; 95(1):17-23. PubMed ID: 38587340 [TBL] [Abstract][Full Text] [Related]
60. Prophylaxis with respiratory syncytial virus F-specific humanized monoclonal antibody delays and moderately suppresses the native antibody response but does not impair immunity to late rechallenge. Fisher RG; Johnson JE; Dillon SB; Parker RA; Graham BS J Infect Dis; 1999 Sep; 180(3):708-13. PubMed ID: 10438358 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]